> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Intellia Reports Positive Data on Gene Therapy
- URL: https://www.fdaweb.com/intellia-reports-positive-data-on-gene-therapy/
- Published: 2024-10-24T12:00:00.000Z
- Updated: 2026-09-14T14:45:00.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5158048

Intellia Therapeutics says new data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary angioedema (HAE) suggest the CRISPR-based gene editing therapy has the potential to eliminate HAE attacks following a one-time infusion. Results were published [online](https://www.globenewswire.com/Tracker?data=WbAsOn2Dt5%5FO508om1jBKnLkbrgfJBcQNwEU5Srs2k84xpHbW1OVz0XCQv5OVq2EYl1UdCdrGxHO8ZXdvaU0jUEm3m%5Fu3gaUUMuX5-9-tn-D-eVsiJD9GEJc%5FzEb8KkYyz5WVgWQ%5FdFSc0nrZuBbQwLwu9Z5dK5TP3-324REjIpXECKoYiZtEQGJ8FCg1FWM&ref=fdaweb.com) 10/24 in *The New England Journal of Medicine.* Based on the results, the company says it is progressing to a planned pivotal Phase 3 (HAELO) study.

“The Phase 2 data demonstrated that a majority of patients in the 50 mg arm experienced a complete response — no attacks at all and no further treatment needed — after a one-time infusion of NTLA-2002 through the latest follow-up, consistent with the long-term Phase 1 data,” the company says. It adds that approved HAE therapies can reduce but frequently do not eliminate all angioedema attacks and require chronic administration.

Intellia says that during the study NTLA-2002 was well tolerated. The most frequent adverse events were headache, fatigue and nasopharyngitis, it says, adding that no clinically significant laboratory abnormalities were observed.